芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的效果分析

Effect Analysis of Qiliqiangxin Capsule Combined with Sacubitril Valsartan for Chronic Heart Failure

目的 探讨芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的效果。方法 选择2022年1月-2023年6月重庆市永川区人民医院收治的90例慢性心力衰竭患者作为研究对象,根据随机数表法将患者随机分为联合组和对照组各45例。联合组采用芪苈强心胶囊联合沙库巴曲缬沙坦治疗,对照组采用沙库巴曲缬沙坦治疗。比较两组疗效及治疗期间的不良反应发生情况,以及治疗前后心功能(左室射血分数、心脏指数、每搏输出量)和运动耐量(6 min步行距离、动脉血氧饱和度)。结果 联合组临床总有效率95.56%,高于对照组的82.22%,差异有统计学意义(χ^(2)值为4.050,P<0.05)。治疗后两组左室射血分数、心脏指数、每搏输出量、6 min步行距离、动脉血氧饱和度均优于治疗前,且联合组优于对照组,差异有统计学意义(P<0.05)。联合组总不良反应发生率13.33%,低于对照组的17.78%,差异无统计学意义(χ^(2)值为0.338,P>0.05)。结论 芪苈强心胶囊联合沙库巴曲缬沙坦治疗慢性心力衰竭的效果,优于单独使用沙库巴曲缬沙坦治疗,且能进一步改善患者心功能、提高活动耐量,具有较好的安全性,值得临床推广使用。

Objective To explore the clinical effect of Qiliqiangxin capsule combined with sacubitril valsartan in the treatment of chronic heart failure(CHF).Methods A total of 90 patients with CHF admitted to the Yongchuan District People's Hospital of Chongqing from January 2022 to June 2023 were selected as the research objects,and all patients were randomly divided into a combination group and a control group with 45 cases in each group.The combination group was treated with Qiliqiangxin capsules combined with sacubitril valsartan,while the control group was treated with sacubitril valsartan alone.Compare the eficacy and incidence of adverse reactions during treatment between two groups,as well as the cardiac function[left ventricular ejection fraction(LVEF),cardiac index(CI),stroke volume(SV)]and exercise tolerance[6-min walking distance,arterial oxygen saturation(SaO_(2))]before and after treatment.Results The total clinical effective rate of the combination group was 95.56%,which was significantly higher than the control group's 82.22%(x^(2) value was 4.050,P<0.05).After treatment,the LVEF,CI,SV,6-min walking distance,and SaO_(2)of the two groups were all better than before treatment,and the combination group were significantly better than those of the control group(P<0.05).The total incidence of adverse reactions in the combination group was 13.33%,lower than the control group's 17.78%,and the difference was not significant(x^(2) value was 0.338,P>0.05).Conclusion The combination of Qiliqiangxin capsules and sacubitril valsartan has a better therapeutic effect on chronic heart failure than the use of sacubitril valsartan alone.It can further improve the patient's heart function,increase activity tolerance,and has good safety,which is worthy of clinical promotion and use.